Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

ABSTRACT: Our findings demonstrate that CDCP1 is a novel modulator of HER2 signalling, and a biomarker for the stratification of breast cancer patients with poor prognosis GEP analysis of human breast cancer cell lines SKBR3 overexpressing CDCP1 and control.

ORGANISM(S): Homo sapiens

SUBMITTER: Francesco Bertoni

PROVIDER: E-GEOD-67019 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models

Project description:we report characterized the preclinical activity of a new member of this class, the ST1926-derivative ST5589, in lymphomas GEP analysis of 2 lymphoma cell lines with and without treatment

2016-01-08 | E-GEOD-66455 | biostudies-arrayexpress

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

Project description:Our findings demonstrate that CDCP1 is a novel modulator of HER2 signalling, and a biomarker for the stratification of breast cancer patients with poor prognosis

2016-01-08 | GSE67019 | GEO

Modulation of microRNA-194 and Cell Migration by HER2-targeting Trastuzumab in Breast Cancer

Project description:We found that trastuzumab (herceptin) treatment significantly decreased five miRNAs and increased three others in SKBr3 cells, whereas in BT474 cells it significantly decreased two miRNAs and increased nine. The only miRNA that shared the same change in both cell lines was miRNA-194 (miR-194), which was upregulated following trastuzumab treatment.

2013-01-31 | E-MTAB-965 | biostudies-arrayexpress

Mouse placenta irradiaion

Project description:External ionizing Irradiation of pregnant mice at E13.5 4 Gy, gene expression at E17.5 On E13.5, female C57Bl/6HN mice were irradiated (total body) at 0 Gy (sham) or 4 Gy using a Gamma Cell cesium irradiator (JL Shepherd, San Fernando, CA), with a dose rate of 70 cGy/min. The mice were monitored for 4 days, and on E17.5, they were sacrificed, and placentas were procured and processed for RNA extrtaction.

2013-08-16 | E-GEOD-49923 | biostudies-arrayexpress

Pharmacogenomic profiling of Akt in helper T cell activation

Project description:1) identify, at the genome-wide level, the genes that are differentially expressed in activated Th cells, with or without Akt inhibition and 2) conduct bioinformatics analyses to identify the pathways and possible mechanisms involved. First identify the differentially expressed genes at 2,6 and 12h time points after TCR stimulation compared with 0h time point in the absence of Akti1/2 and presence of Akti1/2 , then identify differentially expressed gene sets that were dependent on Akt among the three different time point groups . There are duplicate samples for each time point.

2013-03-16 | E-GEOD-45221 | biostudies-arrayexpress

PMCA2 Regulates HER2 Expression, Cell-Surface Localization and Signaling, and Promotes HER2- Mediated Breast Cancer

Project description:In the normal breast, PMCA2 transports calcium into milk. It is also upregulated in breast cancer cells and high tumor levels predict increased mortality in patients. In this study, we examined interactions between PMCA2 and HER2. We find that PMCA2 and a scaffolding protein, NHERF1, interact together with HER2 in specific membrane domains protruding from the surface of breast cancer cells. Knocking down PMCA2 or NHERF1 increases intracellular calcium and leads to the ubiquitination, endocytosis and degradation of HER2 after receptor activation. This is associated with reductions in HER2 expression and signaling. Manipulating PMCA2 levels regulates proliferation and apoptosis of breast cancer cells in vitro and knocking out PMCA2 dramatically inhibits the formation of hyperplasia and tumors in MMTV-Neu mice. Gene expression profiling was performed on control SKBR3 cells vs. PMCA2, NHERFR1 and HER2 knock down cells. Each group has 6 duplicates.

2014-10-22 | E-GEOD-62555 | biostudies-arrayexpress

Human HER2-breast cancer cell line, trastuzumab-resistant, LC-MSMS

Project description:We established an acquired trastuzumab-resistant model in vitro from a trastuzumab-sensitive, HER2-amplified breast-cancer cell line. A multi-omic strategy was implemented to obtain gene, proteome, and phosphoproteome signatures associated with acquired resistance to trastuzumab in HER2-positive breast cancer, followed by validation in human clinical samples.

2020-06-01 | PXD010574 | Pride

A long noncoding RNA landscape in breast cancer reveals a potential role for lncRNA AC009283.1 in proliferation and apoptosis in HER2-enriched molecular subtype

Project description:We silenced lncRNA AC009283.1 using shRNAs in cell line SKBR3, carried a ~75% silencing compared to thenegative control (NC). We evaluated the role of lncRNA AC009283.1 on oncogenic phenotypes in the HER2-enriched SKBR3 breast cancer cell line model. The knockdown of lncRNA AC009283.1 was achieved with ~75% of silencing efficiency. A complete transcriptomic analysis after silencing of lncRNA AC009283.1 revealed an impact on the global expression.

2020-08-12 | GSE134254 | GEO

Gene profiling of HER2 breast cancer patients treated with adjuvant trastuzumab

Project description:The human epidermal growth factor receptor 2 (HER2) gene encodes a tyrosine kinase receptor that controls important signal transduction pathways in breast cancer. Amplification and overexpression of the HER2 gene occurs in approximately 20% of breast cancers and is associated with an aggressive clinical phenotype. Trastuzumab, a humanized monoclonal antibody that targets HER2 showed exceptional efficacy in the treatment of breast cancer. In the adjuvant treatment of breast cancer patients, five randomized trials showed significant benefit of trastuzumab, with a reduction in the rate of recurrence of approximately 50% and improvement in the rate of survival of approximately 30%. In the current study, positive early stage breast cancer samples treated with adjuvant trastuzumab provided by institute Jules Bordet (IJB) and KUL. Gene expression and clinical outcome data were available. to better understand the genetic regulations and effects of the trastuzumab, we profile the the genes expression of positive early stage breast cancer samples treated with adjuvant trastuzumab.

2016-12-31 | GSE58984 | GEO

Irradiation of human and mouse placental cells

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-08-16 | E-GEOD-49924 | biostudies-arrayexpress